Voyager Therapeutics VYGR Stock
Voyager Therapeutics Price Chart
Voyager Therapeutics VYGR Financial and Trading Overview
| Voyager Therapeutics stock price | 3.27 USD |
| Previous Close | 3.13 USD |
| Open | 3.07 USD |
| Bid | 2.32 USD x 200 |
| Ask | 4 USD x 200 |
| Day's Range | 3.07 - 3.29 USD |
| 52 Week Range | 2.94 - 5.55 USD |
| Volume | 469.23K USD |
| Avg. Volume | 642.76K USD |
| Market Cap | 201.49M USD |
| Beta (5Y Monthly) | 1.308 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.81 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.89 USD |
VYGR Valuation Measures
| Enterprise Value | 82.21M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.0958045 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.5212 |
| Price/Book (mrq) | 1.1354166 |
| Enterprise Value/Revenue | 2.253 |
| Enterprise Value/EBITDA | -0.685 |
Trading Information
Voyager Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.308 |
| 52-Week Change | 6.16% |
| S&P500 52-Week Change | 21.71% |
| 52 Week High | 5.55 USD |
| 52 Week Low | 2.94 USD |
| 50-Day Moving Average | 3.41 USD |
| 200-Day Moving Average | 3.88 USD |
VYGR Share Statistics
| Avg. Volume (3 month) | 642.76K USD |
| Avg. Daily Volume (10-Days) | 506.92K USD |
| Shares Outstanding | 61.62M |
| Float | 43.21M |
| Short Ratio | 5.07 |
| % Held by Insiders | 15.13% |
| % Held by Institutions | 57.14% |
| Shares Short | 3.84M |
| Short % of Float | 7.45% |
| Short % of Shares Outstanding | 6.34% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1167.37% |
| Gross Margin | -243.48% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.054% |
| Return on Equity (ttm) | -52.25% |
Income Statement
| Revenue (ttm) | 36.49M USD |
| Revenue Per Share (ttm) | 0.62 USD |
| Quarterly Revenue Growth (yoy) | -59.89% |
| Gross Profit (ttm) | -88856000 USD |
| EBITDA | -119943000 USD |
| Net Income Avi to Common (ttm) | -116637000 USD |
| Diluted EPS (ttm) | -1.81 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 141.48M USD |
| Total Cash Per Share (mrq) | 2.34 USD |
| Total Debt (mrq) | 34.57M USD |
| Total Debt/Equity (mrq) | 19.9 USD |
| Current Ratio (mrq) | 8.422 |
| Book Value Per Share (mrq) | 2.88 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -127991000 USD |
| Levered Free Cash Flow (ttm) | -80829624 USD |
Profile of Voyager Therapeutics
| Country | United States |
| State | MA |
| City | Lexington |
| Address | 75 Hayden Avenue |
| ZIP | 02421 |
| Phone | 857 259 5340 |
| Website | https://www.voyagertherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 141 |
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Q&A For Voyager Therapeutics Stock
What is a current VYGR stock price?
Voyager Therapeutics VYGR stock price today per share is 3.27 USD.
How to purchase Voyager Therapeutics stock?
You can buy VYGR shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Voyager Therapeutics?
The stock symbol or ticker of Voyager Therapeutics is VYGR.
Which industry does the Voyager Therapeutics company belong to?
The Voyager Therapeutics industry is Biotechnology.
How many shares does Voyager Therapeutics have in circulation?
The max supply of Voyager Therapeutics shares is 61.62M.
What is Voyager Therapeutics Price to Earnings Ratio (PE Ratio)?
Voyager Therapeutics PE Ratio is now.
What was Voyager Therapeutics earnings per share over the trailing 12 months (TTM)?
Voyager Therapeutics EPS is -1.81 USD over the trailing 12 months.
Which sector does the Voyager Therapeutics company belong to?
The Voyager Therapeutics sector is Healthcare.
Voyager Therapeutics VYGR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26690.62 USD — |
+1.3
|
7.21B USD — | 26478.01 USD — | 26712.62 USD — | — - | 7.21B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13105.24 USD — |
+1.29
|
— — | 13002.2 USD — | 13116.31 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1293.16 USD — |
+2.08
|
— — | 1273.79 USD — | 1294.2 USD — | — - | — — |
- {{ link.label }} {{link}}
